Edition:
United States

Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)

CRBP.OQ on NASDAQ Stock Exchange Global Market

7.05USD
12 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$7.05
Open
$7.10
Day's High
$7.15
Day's Low
$7.00
Volume
73,933
Avg. Vol
108,580
52-wk High
$10.50
52-wk Low
$5.35

Chart for

About

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threa... (more)

Overall

Beta: --
Market Cap(Mil.): $386.85
Shares Outstanding(Mil.): 54.87
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 185.97 15.71
EPS (TTM): -- -- --
ROI: -- -11.84 31.93
ROE: -- -36.93 16.16

BRIEF-Corbus Pharmaceuticals Q3 loss per share $0.14

* Corbus Pharmaceuticals reports 2017 third quarter financial results and highlights recent corporate and clinical advancements

Nov 08 2017

BRIEF-Corbus Pharma reports improvement in skin conditions in a mid-stage study

* Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study

Nov 06 2017

BRIEF-Corbus Pharma prices underwritten public offering of common stock

* Corbus Pharmaceuticals Holdings, Inc. prices underwritten public offering of common stock

Oct 24 2017

BRIEF-Corbus Pharmaceuticals Holdings announces proposed public offering of common stock

* Corbus Pharmaceuticals Holdings Inc announces proposed public offering of common stock

Oct 23 2017

BRIEF-Corbus Pharma's inflammatory disease drug succeeds mid-stage study

* Corbus Pharmaceuticals reports positive topline results from phase 2 study in rare autoimmune disease dermatomyositis

Oct 19 2017

BRIEF-Corbus Pharmaceuticals Holdings reports Q2 loss per share $0.15

* Corbus Pharmaceuticals reports 2017 second quarter financial results and provides business update

Aug 09 2017

BRIEF-Corbus Pharmaceuticals presented data from phase 2 study of anabasum for treatment of systemic sclerosis

* Corbus Pharmaceuticals presented data from phase 2 study of anabasum for the treatment of systemic sclerosis at the eular 2017 annual meeting

Jun 15 2017

Earnings vs. Estimates